ORPHA:98844
Classic Hodgkin lymphoma, mixed cellularity type
Publications
681
75.9th percentile
Trials
15
Interventional, condition-specific
Researchers
1,306
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0004633
- UMLS:C0152266
- NCIT:C3517
Additional Mondo synonyms (12)
Hodgkin lymphoma, mixed cellularity · Hodgkin's disease mixed cellularity · Hodgkin's disease, mixed cellularity of unspecified site · Hodgkin's lymphoma mixed cellularity · MCCHL · MCHL · Mixed cellularity Classic Hodgkin lymphoma · classic Hodgkin lymphoma, mixed cellularity type · mixed cellularity Hodgkin lymphoma · mixed cellularity Hodgkin's disease · mixed cellularity Hodgkin's lymphoma · mixed cellularity classical Hodgkin lymphoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
681 matched papers (302 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
15 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
681
681 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
681 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
302 in the last 10 years · medium confidence · 75.9th percentile (publications denominator)
Phrase hits: 681 · MeSH hits: 0
Who's working on it?
1,306
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Hansmann ML5 papers · 2026
Consultation and reference center for lymph node pathology at Dr. Senckenberg Institute of Pathology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
Papers in Europe PMC - 02Nakamura S5 papers · 2023
Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
Papers in Europe PMC - 03Satou A5 papers · 2023
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Papers in Europe PMC - 04Hartmann S4 papers · 2026
Dr. Senckenberg Institute of Pathology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
Papers in Europe PMC - 05Jaffe ES4 papers · 2026
From the Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Papers in Europe PMC - 06Schäfer H4 papers · 2026
Molecular Bioinformatics, Institute of Computer Science, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
Papers in Europe PMC - 07Scharf S4 papers · 2026
Department of Molecular Bioinformatics, Institute of Computer Science, Johann Wolfgang Goethe-University, Frankfurt/Main, Hessen, Germany; Frankfurt Institute for Advanced Studies (FIAS), Frankfurt/Main, Hessen, Germany.
Papers in Europe PMC - 08Takahara T4 papers · 2023
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
Papers in Europe PMC - 09Wang Y4 papers · 2024
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Papers in Europe PMC - 10Wurzel P4 papers · 2026
Department of Molecular Bioinformatics, Institute of Computer Science, Johann Wolfgang Goethe-University, Frankfurt/Main, Hessen, Germany; Frankfurt Institute for Advanced Studies (FIAS), Frankfurt/Main, Hessen, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
15
interventional trials for this specific condition
15 interventional trials matched this specific condition name; none in our sample are currently recruiting. 43 trials are registered for classic Hodgkin lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 9 September 2026
15 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94th percentile).
medium confidence · 94th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
15 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: classic Hodgkin lymphoma
43
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07572123·NOT YET RECRUITING·Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
Uncertain·Conditions: Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT06190067·RECRUITING·Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Uncertain·Conditions: Relapsed Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT07097363·RECRUITING·Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Likely noise·Conditions: B-Cell Non-Hodgkin Lymphoma · Burkitt Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified·Matched via name phraseBoth providers judged irrelevant.
- NCT06377540·RECRUITING·MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
Uncertain·Conditions: Autologous Stem Cell Transplant · Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT07021989·NOT YET RECRUITING·ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Uncertain·Conditions: Hodgkin Lymphoma, Adult · Refractory Hodgkin Lymphoma · Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT06465446·NOT YET RECRUITING·A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
Parent·Conditions: Classic Hodgkin Lymphoma·Matched via name phraseBoth providers judged relevant only to a broader parent category.
- NCT06642792·RECRUITING·A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
Uncertain·Conditions: Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT06170489·RECRUITING·A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
Parent·Conditions: Hodgkin Lymphoma·Matched via name phraseBoth providers judged relevant only to a broader parent category.
- NCT05955105·RECRUITING·A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Uncertain·Conditions: Head and Neck Cancer · Cervical Cancer · Endometrial Cancer · Triple Negative Breast Cancer·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT05039073·RECRUITING·Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Uncertain·Conditions: Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT06916416·NOT YET RECRUITING·Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
Parent·Conditions: Classical Hodgkin Lymphoma·Matched via name phraseBoth providers judged relevant only to a broader parent category.
- NCT05949931·RECRUITING·Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
Uncertain·Conditions: Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT07275216·RECRUITING·Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Uncertain·Conditions: Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT04561206·RECRUITING·Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Uncertain·Conditions: Relapsed Classic Hodgkin Lymphoma·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT06745076·RECRUITING·Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
Parent·Conditions: Advanced Hodgkin Lymphoma · Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8·Matched via name phraseBoth providers judged relevant only to a broader parent category.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 60 · after dedupe 60 · already on CT.gov 0 · kept 0 · parent 11 · uncertain 23 · dropped 26 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Broader / parent-category hits (11)
- ctis·2024-520138-31-00·Authorised, ongoing·PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-517756-35-00·Cancelled·A study to learn about the study medicine called PF-08046032 in people with advanced cancers.
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2026-525263-41-00·Authorised·Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE)
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-519812-15-00·Authorised, ongoing·ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-515624-36-00·Expired·Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressing an anti-CD30-chimeric antigen receptor with 4-1-BB and CD3z costimulatory sequences in patients with Classical Hodgkin lymphoma and non-Hodgkin CD30+ T cell lymphoma.
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-515063-66-00·Authorised, ongoing·Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negative interim PET after 2 chemotherapy cycles (RAFTING-2019)
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-515064-31-00·Authorised, ongoing·Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-518022-33-00·Cancelled·HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-516149-38-00·Expired·A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2023-508478-27-00·Expired·EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study
Parent category — Both providers judged relevant only to a broader parent category.
- ctis·2024-510969-42-00·Expired·A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Parent category — Both providers judged relevant only to a broader parent category.
Uncertain / not reviewed (23)
- ctis·2022-501458-13-01·Authorised, ongoing·Pembro-FLASH - Phase II trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classic Hodgkin Lymphoma
Uncertain — At least one provider returned uncertain or parent-category.
- ctis·2024-520123-83-01·Expired·A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
Uncertain — At least one provider returned uncertain or parent-category.
- ctis·2024-516181-11-00·Authorised, ongoing·VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma
Uncertain — At least one provider returned uncertain or parent-category.
- ctis·2024-512734-15-00·Cancelled·A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-510979-38-00·Cancelled·A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-512686-13-00·Cancelled·A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-514938-20-00·Cancelled·Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-511489-35-00·Cancelled·Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-504403-92-00·Cancelled·A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-512689-32-00·Cancelled·A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-507728-22-00·Authorised, ongoing·A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous Glofitamab following Obinutuzumab Pretreatment in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-510173-34-00·Authorised, ongoing·A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-509270-37-00·Cancelled·A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-510966-18-00·Expired·A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (Transcend FL)
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-509354-58-00·Expired·A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-511747-25-00·Expired·AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-512642-42-00·Authorised, ongoing·Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-508343-48-00·Cancelled·Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-511116-25-00·Cancelled·A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-506267-33-00·Authorised, recruiting·A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-507179-23-00·11·LIGHTBEAM-U01-Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination with Investigational Agents in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors.
skipped — Beyond per-disease secondary LLM cap
- ctis·2024-512089-32-00·Authorised, ongoing·A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
skipped — Beyond per-disease secondary LLM cap
- ctis·2023-509975-17-00·Cancelled·An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma
skipped — Beyond per-disease secondary LLM cap
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Classic Hodgkin lymphoma, mixed cellularity type — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Classic Hodgkin lymphoma, mixed cellularity type" OR "Hodgkin lymphoma, mixed cellularity" OR "Hodgkin's disease mixed cellularity" OR "Hodgkin's disease, mixed cellularity of unspecified site" OR "Hodgkin's lymphoma mixed cellularity" OR "MCCHL" OR "Mixed cellularity Classic Hodgkin lymphoma" OR "mixed cellularity Hodgkin lymphoma" OR "mixed cellularity Hodgkin's disease" OR "mixed cellularity Hodgkin's lymphoma" OR "mixed cellularity classical Hodgkin lymphoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Classic Hodgkin lymphoma, mixed cellularity type" OR "Hodgkin lymphoma, mixed cellularity" OR "Hodgkin's disease mixed cellularity" OR "Hodgkin's disease, mixed cellularity of unspecified site" OR "Hodgkin's disease, mixed cellularity of the unspecified site" OR "Hodgkin's lymphoma mixed cellularity" OR "MCCHL" OR "Mixed cellularity Classic Hodgkin lymphoma" OR "mixed cellularity Hodgkin lymphoma" OR "mixed cellularity Hodgkin's disease" OR "mixed cellularity Hodgkin's lymphoma" OR "mixed cellularity classical Hodgkin lymphoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 15 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"classic Hodgkin lymphoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MCHL
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T02:04:21.844Z